Callan Family Office’s ResMed RMD Stock Holding History

Callan Family Office’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Sell	9,773 -170	-2%	-$35.2K	0.04%	409
2026 Q1	$2.23M	Buy	9,943 +646	+7%	+$161K	0.05%	325
2025 Q4	$2.24M	Buy	9,297 +884	+11%	+$226K	0.05%	332
2025 Q3	$2.3M	Sell	8,413 -327	-4%	-$89.3K	0.07%	245
2025 Q2	$2.25M	Buy	8,740 +2,023	+30%	+$483K	0.07%	259
2025 Q1	$1.5M	Sell	6,717 -61	-0.9%	-$14.2K	0.11%	161
2024 Q4	$1.55M	Buy	+6,778	New	+$1.63M	0.1%	179
2023 Q2	–	Sell	-1,034	Closed	-$226K	–	146
2023 Q1	$226K	Hold	1,034	–	–	0.05%	148
2022 Q4	$215K	Buy	+1,034	New	+$227K	0.07%	96

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Callan Family Office's RMD Position: Q2 2026 in Review

Callan Family Office reduced its ResMed (RMD) stake by 1.7% in Q2 2026, selling an estimated $35.2K and leaving 9,773 shares worth $1.9M. The position accounts for 0.04% of the portfolio, ranked #409.

Callan Family Office first reported a position in RMD in Q4 2022 and has held it in 9 quarters since. The position peaked at $2.3M in Q3 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Callan Family Office held 9,773 shares of ResMed worth $1.9M as of Q2 2026.
Callan Family Office sold 170 ResMed shares in Q2 2026, an estimated $35.2K.
ResMed made up 0.04% of Callan Family Office's portfolio in Q2 2026, its #409 holding.
Callan Family Office first reported a position in ResMed in Q4 2022 and has held it in 9 quarters since.
Callan Family Office's ResMed position peaked at $2.3M in Q3 2025.
882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.